Abvc BiopharmaABVC
13F holders, Q2 2024 (June 30)11holders +3
5new positions
2sold out
1famous investor
$0.77avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, up 3 from Q1 2024. 5 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($43K), Vanguard Group Inc. ($36K) and Avantax Planning Partners, Inc. ($30K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $89K |
| Exits | 2 | $233K |
All 13F filers, Q1 2024 → Q2 2024: 148,542 shares bought and 182,609 shares sold, net −34,067 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | Add +151.0% | 55,225 | $43K |
| Vanguard Group Inc. | 0.00% | No change | 46,947 | $36K |
| Avantax Planning Partners, Inc. | 0.00% | New | 39,000 | $30K |
| Citadel Advisors | 0.00% | New | 25,212 | $20K |
| Northern Trust Corp. | 0.00% | New | 19,135 | $15K |
| XTX Topco Ltd | 0.00% | New | 18,944 | $15K |
| State Street Corp. | 0.00% | New | 12,900 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +5.0% | 2,646 | $2K |
| Bank of America Corp. | 0.00% | Reduce -94.2% | 256 | $198 |
| Spotlight Asset Group, Inc. | 0.00% | No change | 100 | $77 |
| Royal Bank of Canada | 0.00% | No change | 37 | $0 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.